Want to see URGN full AI Analyst Report?
URGN Stock Chart & Stats
$22.54
-$0.02(-0.18%)
At close: 4:00 PM EST
$22.54
-$0.02(-0.18%)
Day’s Range― - ―
52-Week Range$15.04 - $41.92
Previous CloseN/A
Volume157.75K
Average Volume (3M)741.63K
Market Cap
$1.96B
Enterprise Value$957.78
Total Cash (Recent Filing)$141.60M
Total Debt (Recent Filing)$197.09M
Price to Earnings (P/E)―
Beta1.01
Next Earnings
Aug 06, 2026EPS Estimate
-0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.75
Shares Outstanding48,721,703
10 Day Avg. Volume892,170
30 Day Avg. Volume741,633
Financial Highlights & Ratios
PEG Ratio-0.94
Price to Book (P/B)-10.68
Price to Sales (P/S)10.26
P/FCF Ratio-6.92
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$41.50Price Target Upside84.12% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.72
Revenue Forecast (FY)$276.43M
Bulls Say, Bears Say
Bulls Say
Revenue Growth & High Gross MarginsSustained top-line expansion from $48M (2021) to $140.5M TTM combined with very high gross margins (~88–90%) creates durable operating leverage. As commercialization scales, these margins can fund SG&A and R&D, improving the path to sustainable profitability if revenue growth persists.
ZUSDURI Early Commercial TractionRapid prescriber growth and repeat usage demonstrate meaningful adoption of ZUSDURI, while improved PEF‑to‑start cycle times and >95% access indicate durable commercial execution. These structural gains increase the likelihood of a continued revenue ramp as coverage and clinician familiarity deepen.
Jelmyto Patent SettlementResolving litigation and agreeing a dated generic entry reduces legal uncertainty and preserves Jelmyto exclusivity through 2030. This structural outcome protects near‑to‑mid‑term revenue streams, lowers litigation costs, and allows management to focus capital and resources on launches and pipeline execution.
Bears Say
Large Cash BurnPersistently negative operating and free cash flows reflect heavy cash consumption to fund launches and operations. This structural cash burn increases reliance on external financing, constrains strategic flexibility, and raises dilution or refinancing risk unless operating cash generation materially improves.
Weak Balance Sheet & Rising LeverageNegative shareholder equity and materially higher debt reduce financial resilience and increase interest and covenant risk. Elevated leverage limits ability to absorb shocks, narrows strategic options for M&A or investment, and makes future financing more costly if commercial progress stalls.
Elevated SG&A And Ongoing LossesHigh launch‑related SG&A sustains substantial operating losses despite revenue gains. Until sales of ZUSDURI and JELMYTO scale enough to offset these expenses, the company will struggle to generate operating profits, maintaining pressure on cash and requiring continued external funding.
Urogen Pharma News
URGN FAQ
What was Urogen Pharma’s price range in the past 12 months?
Urogen Pharma lowest stock price was $15.04 and its highest was $41.91 in the past 12 months.
What is Urogen Pharma’s market cap?
Urogen Pharma’s market cap is $1.96B.
When is Urogen Pharma’s upcoming earnings report date?
Urogen Pharma’s upcoming earnings report date is Aug 06, 2026 which is in 15 days.
How were Urogen Pharma’s earnings last quarter?
Urogen Pharma released its earnings results on May 06, 2026. The company reported -$0.47 earnings per share for the quarter, beating the consensus estimate of -$0.482 by $0.012.
Is Urogen Pharma overvalued?
According to Wall Street analysts Urogen Pharma’s price is currently Undervalued.
Does Urogen Pharma pay dividends?
Urogen Pharma does not currently pay dividends.
What is Urogen Pharma’s EPS estimate?
Urogen Pharma’s EPS estimate is -0.27.
How many shares outstanding does Urogen Pharma have?
Urogen Pharma has 48,721,703 shares outstanding.
What happened to Urogen Pharma’s price movement after its last earnings report?
Urogen Pharma reported an EPS of -$0.47 in its last earnings report, beating expectations of -$0.482. Following the earnings report the stock price went up 10.155%.
Which hedge fund is a major shareholder of Urogen Pharma?
Currently, no hedge funds are holding shares in URGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Urogen Pharma Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$41.50 (84.12% Upside)
$41.50 (84.12% Upside)
Blogger Sentiment
Bullish
URGN Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 28.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▲ 0.4%
Last 30 Days ▼ 0.8%
Last 30 Days ▼ 0.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
161.06%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
2.45%
Trailing 12-Months
Company Description
Urogen Pharma
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions. The company’s lead product candidates are UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk NMIBC. It is also developing UGN-301, UGN-301+UGN 201, and UGN-301+gemcitabine that are in phase 1 of clinical trial for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 and UGN-104. UroGen Pharma Ltd. was incorporated in 2004 and is headquartered in Princeton, New Jersey.
URGN Stock 12 Month Forecast
Average Price Target
$41.50
▲(84.12% Upside)
Technical Analysis
Geron
―
Arbutus Biopharma
―
Phathom Pharmaceuticals
―
Taysha Gene Therapies
―
Zenas BioPharma, Inc.
―
Ownership Overview
1.90% Insiders
5.17% Mutual Funds
0.62% Other Institutional Investors
85.14% Public Companies and
Individual Investors